Overview

A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease (DED)

Status:
Completed

Trial end date:
2021-01-12

Target enrollment:

Participant gender:

Summary

Protocol AXR201701 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 stages (Stage 1: AXR-159 Ophthalmic Solution (30 mg/mL or 50 mg/mL); Stage 2: AXR-159 Ophthalmic Solution (3 mg/mL, 30 mg/mL or 50 mg/mL) in approximately 430 patients diagnosed with dry eye disease (DED).

Phase:

Phase 2

Details

Lead Sponsor:

AxeroVision, Inc.

Collaborator:

ORA, Inc.

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions